Tiziana Life Sciences (Nasdaq:TLSA) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TLSA Overzicht aandelen

TLSA fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

De winst is de afgelopen 5 jaar met 12.3% per jaar gedaald

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen betekenisvolle marktkapitalisatie ( $97M )

Tiziana Life Sciences Ltd Concurrenten

Anixa Biosciences

NasdaqCM:ANIX

US$101.4m

Coya Therapeutics

NasdaqCM:COYA

US$104.0m

Lirum Therapeutics

NasdaqCM:LRTX

US$102.0m

Leap Therapeutics

NasdaqCM:LPTX

US$94.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tiziana Life Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$1.00
52 Week Hoogtepunt	US$1.74
52 Week Laag	US$0.41
Bèta	0.18
11 maand verandering	8.70%
3 maanden verandering	20.48%
1 Jaar Verandering	37.93%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-33.33%

Recent nieuws en updates

Recent updates

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct 12

Tiziana chief medical officer further increases holdings in company

Sep 23

Tiziana Life Sciences executive chairman further raises stake in company

Sep 16

Tiziana executive chairman raises stake in company again, buys more shares

Aug 25

Tiziana Life Sciences discloses share purchase by executive chairman

Aug 17

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Aug 15

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Jul 15

Rendement voor aandeelhouders

	TLSA	US Biotechs	US Markt
7D	-1.0%	-0.5%	0.3%
1Y	37.9%	18.0%	32.4%

Rendement versus industrie: TLSA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.

Rendement versus markt: TLSA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is TLSA's price volatile compared to industry and market?
TLSA volatility
TLSA Average Weekly Movement	16.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van TLSA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 16% ) van TLSA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	9	Gabriele Marco Cerrone	www.tizianalifesciences.com

Tiziana Life Sciences Ltd, een biotechnologiebedrijf, richt zich op het ontdekken en ontwikkelen van moleculen voor de behandeling van menselijke ziekten in de oncologie en immunologie in de Verenigde Staten. De belangrijkste productkandidaat van het bedrijf in immunologie is Foralumab (TZLS-401), een humaan anti-CD3 monoklonaal antilichaam (mAb) voor de behandeling van de ziekte van Crohn, graft versus host, colitis ulcerosa, multiple sclerose, diabetes type 1, inflammatoire darmziekten, psoriasis en reumatoïde artritis. Het ontwikkelt ook Milciclib (TZLS-201), een oraal biobeschikbare kleine molecule breed spectrum remmer van verschillende cycline-afhankelijke kinasen en Src-familie; en TZLS-501, een volledig humaan mAb gericht tegen de IL-6 receptor voor de behandeling van ontstekings- en oncologie-indicaties.

Tiziana Life Sciences Ltd Samenvatting

Hoe verhouden de winst en inkomsten van Tiziana Life Sciences zich tot de beurswaarde?
TLSA fundamentele statistieken
Marktkapitalisatie	US$99.87m
Inkomsten(TTM)	-US$17.69m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-5.7x

Koers/Winstverhouding

Is TLSA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TLSA resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$17.69m
Inkomsten	-US$17.69m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.17
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde TLSA op de lange termijn?

Bekijk historische prestaties en vergelijking

TLSA Overzicht aandelen

Beloningen

Risicoanalyse

Tiziana Life Sciences Ltd Concurrenten

NasdaqCM:ANIX

US$101.4m

NasdaqCM:COYA

US$104.0m

NasdaqCM:LRTX

US$102.0m

NasdaqCM:LPTX

US$94.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Recent updates

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Chief Executive Officer Changes

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Insufficient new directors

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

Tiziana Life Sciences, Ltd. Announces Qualitative Results for All 10 Non-Active Secondary Progressive Multiple Sclerosis (Na-Spms) Patients Enrolled in the Intermediate-Size Patient Population Expanded Access (Ea) Program

Tiziana Life Sciences Ltd announced delayed 20-F filing

Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology

New minor risk - Share price stability

Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Tiziana Life Sciences Ltd Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Tiziana Life Sciences Ltd. Doses First Patient in Phase 2A Trial of Intranasal Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 14, 2023

Tiziana Life Sciences Ltd. Announces Successfully Enrolled and Dosed Four New Patients with Non-Active Secondary Progressive Multiple Sclerosis

New minor risk - Financial data availability

Tiziana Life Sciences Ltd. Announces Allowance by Fda for At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis Treatment

Tiziana Life Sciences Ltd. Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Tiziana Announces Positive Qualitative Six-Month Pet Scan Results with Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed with Non-Active Secondary Progressive MS (Na-SPMS)

Tiziana Life Sciences Ltd. Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer, Effective September 1, 2023

New major risk - Share price stability

Insufficient new directors

Tiziana Life Sciences Ltd Appoints Matthew Davis as Its New Chief Operating Officer

New minor risk - Market cap size

Tiziana Life Sciences Ltd. Announces Reduction in Microglial Activation in Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate

Will Tiziana Life Sciences (NASDAQ:TLSA) Spend Its Cash Wisely?

Tiziana Life Sciences Announces IND Filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer

Tiziana Life Sciences Ltd Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (Spms) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd Announces Completion of Prerequisite Pre-Clinical Safety Study

Tiziana Life Sciences Ltd. Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirements

Tiziana Life Sciences Ltd, Annual General Meeting, Dec 29, 2022

Tiziana Life Sciences Ltd Announces Publication of A Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T Cell Function and an Induced T Cell Regulatory Response in Human Subjects

Less than half of directors are independent

Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (Cns)

Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for Its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in Its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

Tiziana Life Sciences Ltd. Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients

Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Tiziana chief medical officer further increases holdings in company

Tiziana Life Sciences Ltd Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (Spms) After Six Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd(NasdaqGM:TLSA) dropped from S&P Global BMI Index

Tiziana Life Sciences Announces Grant Received by the Brigham and Women’S Hospital to Explore the Use of Intranasal Anti-Cd3 Mab in Amyotrophic Lateral Sclerosis

Tiziana Life Sciences executive chairman further raises stake in company

Tiziana executive chairman raises stake in company again, buys more shares

Tiziana Life Sciences discloses share purchase by executive chairman

Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Tiziana Life Sciences Appoints Matthew W. Davis as Chief Medical Officer and Acting Chief Scientific Officer

Tiziana Life Sciences Ltd Announces Resignation of Kunwar Shailubhai as Chief Scientific Officer and Board Director

Tiziana Life Sciences CEO Kunwar Shailubhai resigns

Tiziana Life Sciences Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Rules